CGM Sensors: How Real-Time Glucose Monitoring Is Changing Diabetes Treatment

From Fingersticks to Continuous Monitoring

For decades, glucose self-monitoring meant fingerstick glucometers — devices that provide a single glucose value at one moment in time. It is like assessing the weather from a single daily snapshot. Continuous glucose monitoring (CGM) systems changed the paradigm: they measure interstitial fluid glucose every 1-5 minutes, generating up to 288 data points per day.

The CGM market reached $8.2 billion in 2024 and is projected to exceed $15 billion by 2028. The technology has expanded well beyond type 1 diabetes — CGM is now used by patients with type 2 diabetes, prediabetes, and even metabolically healthy individuals seeking optimization.

How CGM Sensors Work

A CGM sensor is a miniature electrochemical biosensor inserted subcutaneously (typically on the back of the upper arm or abdomen). A thin filament electrode (5-7 mm long, <0.4 mm diameter) is coated with glucose oxidase enzyme, which catalyzes glucose oxidation in interstitial fluid. The generated electrical current is proportional to glucose concentration.

Data is transmitted via Bluetooth or NFC to a smartphone or reader. Important: CGM measures interstitial fluid glucose, not blood glucose. There is a physiological 5-15 minute lag between blood and interstitial glucose changes.

Current CGM Systems (2025-2026)

### FreeStyle Libre 3 (Abbott)

• Size: 21.2 mm (smallest CGM sensor globally) - Wear time: 14 days - Readings: every minute - Transmission: Bluetooth Low Energy (continuous) - Accuracy: MARD 7.9% (among the best) - Calibration: factory-calibrated (none required) - Alerts: customizable hypo/hyperglycemia notifications - Water resistance: IP27 (submersion to 1 m for 30 minutes)

### Dexcom G7

• Size: 28 mm (60% smaller than G6) - Wear time: 10 days + 12-hour grace period - Readings: every 5 minutes - Transmission: Bluetooth - Accuracy: MARD 8.2% (adults) - Calibration: not required - Integration: compatible with insulin pumps (Omnipod 5, Tandem Mobi) - Unique feature: trend arrows showing rate of change

### Dexcom Stelo (2025)

• First CGM approved by FDA for people not on insulin - Target audience: type 2 diabetes without insulin, prediabetes - Wear time: 15 days - Available OTC (over-the-counter) in the USA - Simplified interface without hypoglycemia alerts

### SiBio KS1 (Ketones)

• First continuous ketone monitor in the world - Wear time: 14 days - Measures beta-hydroxybutyrate (BHB) in interstitial fluid - Ideal for monitoring ketosis (ketogenic diet, intermittent fasting) - Combined with CGM provides complete metabolic picture

Key CGM Metrics

### Time in Range (TIR)

International consensus targets (Battelino et al., Diabetes Care, 2019): - Target range: 70-180 mg/dL (3.9-10.0 mmol/L) - Optimal TIR: >70% (>16 hours 48 minutes per day) - Hypoglycemia (<70 mg/dL): <4% (<58 minutes) - Severe hypoglycemia (<54 mg/dL): <1% - Hyperglycemia (>180 mg/dL): <25% - Severe hyperglycemia (>250 mg/dL): <5%

Each 5% increase in TIR is associated with approximately 0.5% reduction in HbA1c (Beck et al., Annals of Internal Medicine, 2019). TIR >70% correlates with HbA1c <7%.

### Glycemic Variability

Coefficient of Variation (CV) — key glycemic stability indicator. CV <36% is considered stable; CV >36% is unstable with increased hypoglycemia risk. Monnier et al. (Diabetes Care, 2017) demonstrated that glycemic variability is an independent risk factor for cardiovascular complications.

Ambulatory Glucose Profile (AGP) — a standardized report combining 14 days of data into one visual picture: median, 25th/75th percentiles, 5th/95th percentiles.

Practical Applications

### Type 1 Diabetes

CGM + insulin pump = hybrid closed-loop system. The algorithm automatically adjusts basal insulin based on CGM data. NEJM (2022): such systems increased TIR from 51% to 68% in adolescents with T1D.

### Type 2 Diabetes

FLASH-UK study (Lancet, 2022): FreeStyle Libre in T2D patients on insulin reduced HbA1c by 0.5% and decreased time in hypoglycemia by 43%. CGM helps patients see the impact of specific foods, physical activity, and stress on glucose.

### Prediabetes and Metabolic Health

A two-week CGM trial enables: identifying individual glycemic responses to foods, detecting hidden glucose spikes (reactive hypoglycemia, nocturnal elevations), assessing the impact of sleep and stress, and motivating behavioral change through visual biofeedback.

CGM Limitations

• Lag time: 5-15 minute delay — critical during rapid changes - Extreme range accuracy: lower at <70 and >300 mg/dL - First 24 hours: less accurate readings (stabilization period) - Compression lows: false hypoglycemia from pressure on sensor during sleep - Interference: acetaminophen may elevate readings on older models - Cost: $75-300/month without insurance

How to Start Using CGM

1. Define your goal: diabetes management, metabolic optimization, ketosis monitoring 2. Choose a system: FreeStyle Libre 3 (best value), Dexcom G7 (best pump integration) 3. Set duration: minimum 14 days for a complete picture 4. Keep a food diary: correlate meals with glycemic responses 5. Physician interpretation: present the AGP report to your endocrinologist

Frequently Asked Questions

Do I need CGM for type 2 diabetes without insulin? Even a short course (2-4 weeks) provides valuable insights. Dexcom Stelo was FDA-approved specifically for this group. Visual biofeedback motivates behavioral change.

Does CGM replace a glucometer? For most decisions, yes. However, when accuracy is in doubt (compression, rapid change), a confirmatory fingerstick is recommended.

Can a healthy person benefit from CGM? Yes, for metabolic optimization. It reveals individual food responses and hidden insulin resistance. A 2-4 week course is informative.

Is CGM insertion painful? Most users describe a light click sensation. The filament electrode is so thin that it is typically not felt after insertion.

*This article is for educational purposes only. CGM system selection and data interpretation should be done in consultation with your healthcare provider.*

🌀

MARD, FDA iCGM Criteria, and Accuracy Reporting

Mean Absolute Relative Difference (MARD) is the dominant accuracy metric for continuous glucose monitors. It is calculated as the mean of absolute percentage differences between paired CGM readings and a reference value (typically a YSI 2300 STAT laboratory analyzer or capillary blood glucose), expressed as a single percentage across the full sensor wear period and glucose range. A lower MARD indicates closer agreement with the reference. Modern factory-calibrated sensors report MARD values in the 8–10% range under standardized conditions, but the metric is sensitive to study design — paired-sample density, glucose rate of change, and the proportion of hypoglycemic versus hyperglycemic readings all shift the result PMID: 28733374.

In 2018 the U.S. Food and Drug Administration introduced the integrated CGM (iCGM) regulatory category, the first performance-based classification that permits a sensor to drive automated insulin dosing decisions. To qualify, a device must meet pre-specified accuracy thresholds across the glycemic spectrum: at least 87% of readings within ±15 mg/dL of reference at glucose <70 mg/dL, ≥70% within ±15% at 70–180 mg/dL, and ≥80% within ±15% at >180 mg/dL, with no individual reading deviating by more than ±40% from reference and a confirmed sensor failure rate under 5%. Dexcom G6 was the first sensor authorized under this pathway; the G7 and FreeStyle Libre 3 subsequently received iCGM clearance under the same framework.

MARD alone can mask clinically important error patterns, which is why the Consensus Error Grid (Parkes) and Surveillance Error Grid are reported alongside it. These plots categorize each paired reading into clinical-action zones — Zone A indicates no effect on clinical decisions, Zone B minor or no effect, and Zones C–E progressively higher risk of incorrect treatment. For an iCGM-class device, virtually all readings must fall in Zones A and B PMID: 28854083. The Surveillance Error Grid was specifically designed to weight hypoglycemic errors more heavily than hyperglycemic ones, reflecting the greater acute danger of missed lows.

Several caveats apply when interpreting manufacturer MARD figures. First, accuracy is consistently worse on day 1 of wear during sensor stabilization and on the final day as the enzymatic membrane degrades, a pattern documented across multiple pivotal trials PMID: 27330126. Second, MARD is reported as an aggregate, but published subgroup analyses show 15–30% relative worsening in the hypoglycemic range (<70 mg/dL) where decision stakes are highest. Third, the metric is dependent on the rate of glucose change: during periods of rapid change (>2 mg/dL/min), the physiological 5–15 minute interstitial-to-plasma lag inflates apparent error even when the sensor itself is performing within specification. Clinicians evaluating a patient's CGM report should not equate a single sensor session's pattern with population MARD without considering these factors.

🌀

Substance Interference: Mechanisms and Thresholds

Most modern CGM electrodes use immobilized glucose oxidase to catalyze glucose oxidation, generating hydrogen peroxide whose oxidation at the working electrode produces the measured current. Any substance that is itself electrochemically active at the operating potential, or that competes with glucose for the enzyme, can produce a measurement artefact.

Acetaminophen (paracetamol) is the best-characterized interferent. At plasma concentrations above approximately 5 mg/dL — reached after a standard 1 g oral dose — acetaminophen is directly oxidized at the platinum working electrode of older Dexcom G4 and G5 sensors, falsely elevating glucose readings by 30–80 mg/dL. The Dexcom G6 and G7 incorporate a selective membrane that eliminates this effect at therapeutic doses, though supratherapeutic exposures (>4 g/24 h) may still cause artefact PMID: 28939505. FreeStyle Libre sensors are reported by the manufacturer as resistant to acetaminophen at therapeutic doses.

Ascorbic acid (vitamin C) is a second important interferent for FreeStyle Libre devices specifically. Supplemental doses above 500 mg can produce falsely elevated readings of 20–40 mg/dL because ascorbate is co-oxidized at the sensor electrode. The effect is dose-dependent and dissipates within 4–6 hours PMID: 28939506. Hydroxyurea, used in sickle cell disease and certain hematologic conditions, has been documented to cause clinically significant Dexcom overestimation and is currently listed as a contraindication for that platform.

Mannitol, used intraoperatively and in neurology, can affect both interstitial volume and the sensor reaction. Salicylates at high doses (>3 g/day), tetracycline, and certain peritoneal dialysis solutions containing icodextrin (which is metabolized to maltose and cross-reacts with non-glucose-specific glucometers) have all been reported in case literature to produce sensor artefact. Patients on these agents should confirm anomalous CGM readings with a laboratory glucose before treatment decisions, particularly insulin dosing.

🌀

Compression Artefacts and Sensor Placement Strategy

Compression-induced pressure artefacts — colloquially "compression lows" — occur when sustained pressure on the sensor site reduces local interstitial fluid flow, causing transient apparent hypoglycemia despite normal blood glucose. The mechanism is mechanical: capillary perfusion in the dermal-subcutaneous interface decreases under pressure greater than approximately 30 mmHg, reducing glucose delivery to the sensor microenvironment faster than equilibration can compensate. Readings typically fall by 20–50 mg/dL over 15–45 minutes and rebound within minutes of pressure relief PMID: 31049640.

The phenomenon is most often nocturnal because patients sleep on the sensor unknowingly. Published series identify side-sleeping on the sensor arm, weight-bearing during exercise, and tight clothing waistbands over abdominal sensors as the principal triggers. The artefact is essentially indistinguishable from genuine hypoglycemia on the trace alone; the discriminating features are abrupt onset without preceding downward trend, rapid spontaneous recovery upon position change, and absence of symptoms.

Site selection mitigates risk. The back of the upper arm — the labeled site for FreeStyle Libre 3 and Dexcom G7 — is preferred because it is less subject to weight-bearing pressure than the abdomen or thigh. Rotation between left and right arms each sensor cycle prevents repeated mechanical irritation of the same site and gives subcutaneous tissue time to recover. Patients with recurrent nocturnal lows should be asked specifically whether the events occur on the side they sleep on; switching sensor arm or sleep position resolves a substantial proportion of cases PMID: 32759362.

🌀

CGM in Pregnancy and Gestational Hyperglycemia

The CONCEPTT randomized controlled trial established CGM as standard of care for pregnancy complicated by type 1 diabetes. In 325 women randomized to CGM versus self-monitored blood glucose during pregnancy or pre-conception, CGM use significantly reduced HbA1c, increased time in the pregnancy-specific target range of 63–140 mg/dL (3.5–7.8 mmol/L), and reduced large-for-gestational-age births, neonatal intensive care admissions exceeding 24 hours, and severe neonatal hypoglycemia PMID: 28854089. The number needed to treat to prevent one adverse neonatal outcome was 6.

Target ranges differ materially from non-pregnant adults. The international consensus recommends time in 63–140 mg/dL >70% of the day, time below 63 mg/dL <4%, time below 54 mg/dL <1%, and time above 140 mg/dL <25%. These tighter targets reflect the increased glucose sensitivity of the placenta and fetal pancreas: maternal hyperglycemia drives fetal hyperinsulinemia and accelerated growth, the mechanistic basis of macrosomia, shoulder dystocia, and neonatal hypoglycemia.

For gestational diabetes specifically, evidence for routine CGM is still developing but supportive. Smaller randomized trials suggest improved glycemic outcomes and possibly reduced cesarean delivery rates, though current professional society guidance does not yet mandate CGM for all GDM. Practical considerations include sensor adhesion in the third trimester as abdominal skin stretches, and avoidance of abdominal placement after the second trimester in favor of the posterior upper arm PMID: 32711642.

🌀

Algorithmic Basis of Hybrid Closed-Loop Systems

Hybrid closed-loop (HCL) systems — also called automated insulin delivery — pair a CGM with an insulin pump and a control algorithm that adjusts basal insulin delivery in response to glucose trajectory. The patient still announces meals and delivers bolus insulin for carbohydrates; the algorithm handles basal modulation and corrects for hyperglycemia or impending hypoglycemia between meals.

Two algorithmic families dominate. Proportional-Integral-Derivative (PID) controllers, used in the Medtronic MiniMed 780G, compute insulin output as a weighted sum of three terms: the proportional error (current glucose minus target), the integral of past error, and the derivative (rate of change). PID is computationally simple and well-validated but reacts to glucose changes rather than anticipating them. Model Predictive Control (MPC), used in the Tandem Control-IQ and Insulet Omnipod 5, builds an internal pharmacokinetic-pharmacodynamic model of the patient's insulin sensitivity and glucose response, then optimizes insulin dosing across a forward time horizon (typically 30–60 minutes). MPC can pre-emptively suspend insulin before predicted hypoglycemia and is generally considered more flexible across diverse patient phenotypes PMID: 30224348.

Trial data show consistent gains. Across pivotal studies of currently marketed HCL systems, time in range increased by 9–14 percentage points compared with sensor-augmented pump therapy without algorithmic control, with simultaneous reductions in time below 70 mg/dL. The clinical implication is that CGM accuracy is not an academic concern in this population: algorithm decisions are made every 5 minutes based on the sensor value, and out-of-range error directly translates into incorrect insulin delivery. This is why the FDA iCGM pathway requires accuracy at hypoglycemic thresholds in addition to overall MARD — a sensor that under-reads in the 60–80 mg/dL range will trigger automated suspensions correctly, whereas one that over-reads in the same range will permit ongoing basal infusion into actual hypoglycemia.